← All supplements
Limited evidenceImmunity

Streptococcus Salivarius K12

An oral probiotic that colonises the throat and produces bacteriocins against Streptococcus pyogenes. Several trials report fewer sore throat and ear infection episodes, but almost all are small and poorly blinded.

Evidence last reviewed: August 2026

What the science says

  • Possible reduction in sore throat episodes Limited evidence

    A systematic review of K12 for treating or preventing sore throat found studies suggesting reduced episodes of streptococcal pharyngitis, while judging the trials small, largely non-blinded and at substantial risk of bias. The reviewers concluded that better trials are needed before recommending it.

  • Ear and oral cavity outcomes Limited evidence

    A systematic review of K12 in ear and oral health reported reductions in recurrent pharyngotonsillitis and acute otitis media across the available studies, again with methodological weaknesses throughout.

  • Paediatric prevention study Limited evidence

    An open-label study in three-year-old children reported fewer episodes of streptococcal pharyngotonsillitis, scarlet fever and acute otitis media over a 90-day treatment plus follow-up. The lack of blinding and placebo control limits what can be concluded.

Dosage & safety

Studied doseOne lozenge providing roughly 1 billion CFU per day, dissolved slowly in the mouth after brushing teeth at night. Studied courses typically ran 30–90 days.
SafetyWell tolerated in the trials. Live-organism probiotics should be avoided by people who are severely immunocompromised, have central venous catheters or are at risk of endocarditis. Lozenges are a choking hazard for very young children — paediatric trials used age-appropriate formulations.

Scientific references

Where to buy

Referral link — this site may earn a commission on purchases.

Related in Immunity